Benmoxin (trade names Neuralex, Nerusil), also known as mebamoxine, is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine class.[1][2] It was synthesized in 1967 and was subsequently used as an antidepressant in Europe, but is now no longer marketed.[1][2]
![]() | |
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.028.745 |
Chemical and physical data | |
Formula | C15H16N2O |
Molar mass | 240.306 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
See also
editReferences
edit- ^ a b Ganellin CR, Triggle DJ (1996). Dictionary of Pharmacological Agents. Vol. 1–2. Chapman & Hall. p. 229. ISBN 0-9630096-0-5.
- ^ a b Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. ISBN 3-88763-075-0.